Launches from companies including Boehringer Ingelheim and Bristol Myers Squibb could drive sales of schizophrenia drugs up to $17 billion by 2031 despite generic erosion of incumbent products, according to GlobalData.
Fierce Pharma is a leading digital publication dedicated to providing comprehensive coverage of the pharmaceutical industry. It serves as a go-to source for news, trends, and insights shaping the ever-evolving pharma landscape.
With a primary focus on healthcare, pharmaceuticals, and wellbeing, Fierce Pharma covers a wide range of topics, including approved drugs, pharmaceutical operations, marketing strategies, manufacturing processes, drug delivery systems, and the latest scientific advancements. The publication's content caters to professionals, researchers, and stakeholders within the pharma industry, offering in-depth analysis and context to complex developments.
Fierce Pharma's team of experienced journalists delivers news and insights through various channels, including online articles, podcasts, and events. Their coverage encompasses press releases, data citations, government announcements, private sector updates, and legal and regulatory developments, ensuring readers stay informed about the most significant happenings in the industry.
In addition to its flagship publication, Fierce Pharma, the platform offers a suite of related publications, such as Fierce Pharma PM Tracker, Fierce Pharma Marketing, Fierce Manufacturing, Fierce Drug Delivery, and Fierce Life Sciences Weekly Digest, catering to specific areas within the broader pharma sector.
Fierce Pharma's commitment to delivering high-quality, insightful content has earned it a loyal following among industry professionals seeking reliable and authoritative information to support their work and stay ahead of the curve.